Tranexamic Acid in Dermatology

S, Soundarya; Srinivasan, M. S.

doi:10.36295/asro.2020.231509

Cited by 4 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TXA is an antifibrinolytic agent that shows a positive effect on wound healing in several studies, and it showed benefits in treating skin diseases like melasma, rosacea erythema and ultraviolet induced pigmentations. 16 Although it has been discovered since 1979, 17 It has attracted the attention of dermatologists recently in the past few years to use it in a refractory, resistant disorder like melasma. It has shown promising effects in all the routes administered like topical, oral or intradermal with minimal side effects.…”

Section: Introductionmentioning

confidence: 99%

A split face comparative study using a novel triple combination therapy for the treatment of persistent post acne erythema

Agamia

El‐Nagdy

Elariny

2022

Dermatologic Therapy

View full text Add to dashboard Cite

Persistent post acne erythema (PAE) is common cosmetically unacceptable and challenging sequelae of acne lesions. Tranexamic acid (TXA) is an antifibrinolytic agent that shows a positive effect on wound healing in several studies, and it showed benefits in treating skin diseases like melasma, rosacea erythema and ultraviolet induced pigmentations. Oxymetazoline (OXZ) is a synthetic, highly selective agonist for alpha 1A‐adrenoceptor. It is a potent vasoconstrictor. OXZ hydrochloride 1% cream was approved by the FDA in January 2017 as a topical treatment for persistent facial erythema in rosacea patients. Brimonidine tartrate (BMT) is highly selective α2 adrenergic receptor agonist, results in direct, potent vasoconstriction of small arterioles and veins. In 2013, brimonidine 0.33% gel was the first topical therapy to be FDA approved for the treatment of persistent facial erythema from rosacea. To evaluate the efficacy and safety of topical triple combination (TXA 5% + OXZ 1.5% + BMT 0.33%) in the treatment of PAE planned as split face comparative study. This study was conducted on 40 patients diagnosed with persistent PAE for at least 3 months, the right side of the face was treated with topical triple combination in liposomal base and was compared to the left side to which topical lipocream (placebo) was applied as a control. Our treatment plan lasted for 3 months. According to the investigator's global assessment of photographs and computerized analysis of erythema using image analysis software, topical triple combination applied on the right side of face was significantly effective in diminishing PAE when compared to topical placebo left side. Topical triple combination is a safe and cost‐effective treatment for PAE.

show abstract

Section: Introductionmentioning

confidence: 99%

A split face comparative study using a novel triple combination therapy for the treatment of persistent post acne erythema

Agamia

El‐Nagdy

Elariny

2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Pada dosis minimal, efek samping juga minimal. 5 Kontraindikasi penggunaan asam traneksamat meliputi gangguan perdarahan dan pembekuan darah, hipersensitivitas terhadap obat, buta warna, stroke, kondisi sumbatan intravaskular aktif, penyakit jantung iskemik, serta tromboemboli vena. 5 Penggunaan asam traneksamat harus dengan pemantauan ketat pada pasien penyakit kardiovaskular serta penyakit pembuluh darah otak.…”

Section: Pendahuluanunclassified

“…5 Kontraindikasi penggunaan asam traneksamat meliputi gangguan perdarahan dan pembekuan darah, hipersensitivitas terhadap obat, buta warna, stroke, kondisi sumbatan intravaskular aktif, penyakit jantung iskemik, serta tromboemboli vena. 5 Penggunaan asam traneksamat harus dengan pemantauan ketat pada pasien penyakit kardiovaskular serta penyakit pembuluh darah otak. Fungsi koagulasi meliputi prothrombin time (PT), activated partial thromboplastin time (APTT), dan parameter pembekuan darah lain harus diperiksa sebelum memulai terapi asam traneksamat.…”

Section: Pendahuluanunclassified

Tinjauan atas Efikasi Asam Traneksamat Oral untuk Terapi Melasma

Triyanti¹

2022

CDK

View full text Add to dashboard Cite

<p>Melasma adalah kondisi hipermelanosit didapat berupa makula tidak merata yang umumnya simetris. Kondisi ini biasanya terlokalisasi dan bersifat kronik-residif. Di antara banyak faktor kausatif yang berperan pada patogenesis melasma, salah satu yang dianggap penting adalah paparan sinar UV pada kulit. Pengobatan melasma penuh tantangan karena sering rekuren. Asam traneksamat adalah plasmin inhibitor yang melalui sistem plasmin-aktivator plasminogen berperan mencegah induksi pigmentasi oleh radiasi UV. Artikel ini bertujuan meninjau efikasi asam traneksamat oral pada terapi melasma.</p><p>Melasma is an acquired hypermelanocyte condition; generally localized, symmetrical in regular macules form and chronic-recidive. Many causative factors may play role in the pathogenesis of melasma, one that is considered important is UV exposure. Despite several treatments available, recurrences are common. Tranexamic acid as plasmin inhibitor acts mainly via the plasminogen activator-plasmin system to prevent UV radiation-induced pigmentation. This review discuss the efficacy of oral tranexamic acid for melasma treatment.</p>

show abstract

“…It prevents side effects and organ damage, such as kidney and bone marrow damage [5,6]. Tranexamic acid is marketed in a tablet dosage form available in strengths of 500 mg per tablet [7]. Drugs marketed must meet aspects of efficacy, quality, and safety [8].…”

Section: Introductionmentioning

confidence: 99%

Validation of the Developed Zero-Order Infrared Spectrophotometry Method for Qualitative and Quantitative Analyses of Tranexamic Acid in Marketed Tablets

et al. 2021

View full text Add to dashboard Cite

(1) Background: The functional groups present in tranexamic acid allow direct infrared detection analysis. This study aimed to develop, apply, and validate an infrared spectrophotometry method used for qualitative and quantitative analyses of tranexamic acid in marketed tablets. (2) Methods: This was a descriptive observational study that consisted of several stages: determining the specific wavenumber for analysis, obtaining a simple linear regression equation, analyzing tranexamic acid both qualitatively and quantitatively, and validating the developed method for routine analysis. (3) Results: The peak analysis obtained a range of baseline wavenumbers from 1679.17 to 1295.25 cm−1. The regression equation obtained was Y = 310.8527 × X + 0.9718, and the coefficient of determination (R2) obtained was 0.9994. The tranexamic acids in marketed tablets overall have a similarity index value of more than 0.90 and overall have levels ranging between 97.0% and 103.0%. The infrared spectrophotometry method that was successfully developed, applied, and validated for qualitative and quantitative analyses of tranexamic acid in marketed tablets meets the requirements both qualitatively and quantitatively of the tablet monograph. (4) Conclusions: The infrared spectrophotometry method has been validated and meets the requirements for accuracy, precision, detection limit, quantitation limit, linearity, range, and specificity.

show abstract

Tranexamic Acid in Dermatology

Cited by 4 publications

References 11 publications

A split face comparative study using a novel triple combination therapy for the treatment of persistent post acne erythema

A split face comparative study using a novel triple combination therapy for the treatment of persistent post acne erythema

Tinjauan atas Efikasi Asam Traneksamat Oral untuk Terapi Melasma

Validation of the Developed Zero-Order Infrared Spectrophotometry Method for Qualitative and Quantitative Analyses of Tranexamic Acid in Marketed Tablets

Contact Info

Product

Resources

About